TerminatedPhase 2NCT03679975

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aquestive Therapeutics
Principal Investigator
Cassie Jung
Aquestive Therapeutics
Intervention
Riluzole Oral Soluble film (ROSF) 50 mg(drug)
Enrollment
9 enrolled
Eligibility
18-80 years · All sexes
Timeline
20182018

Study locations (1)

Collaborators

inVentiv Health Clinical · Covance

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03679975 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials